T. Rowe Price Associates
TECX

T. Rowe Price Associates’s Tectonic Therapeutic TECX Stock Holding History

T. Rowe Price Associates’s Portfolio TECX Stock Details TECX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Sell
48,001
-116,054
-71% -$3.41M ﹤0.01% 2101
2026
Q1 		$5.07M Buy
+164,055
New +$4.04M ﹤0.01% 1415
2025
Q3 		– Sell
-18,322
Closed -$365K – 3138
2025
Q2 		$365K Buy
18,322
+5,515
+43% +$112K ﹤0.01% 2450
2025
Q1 		$227K Buy
+12,807
New +$417K ﹤0.01% 2582
2021
Q1 		– Sell
-2,876
Closed -$481K – 2875
2020
Q4 		$481K Sell
2,876
-72,124
-96% -$12.8M ﹤0.01% 2259
2020
Q3 		$11.7M Sell
75,000
-7,663
-9% -$1.54M ﹤0.01% 1262
2020
Q2 		$17.3M Buy
82,663
+8,118
+11% +$1.67M ﹤0.01% 1181
2020
Q1 		$13.9M Sell
74,545
-5,250
-7% -$1.24M ﹤0.01% 1168
2019
Q4 		$19.3M Sell
79,795
-15,244
-16% -$2.94M ﹤0.01% 1193
2019
Q3 		$16.1M Buy
95,039
+27,686
+41% +$6.27M ﹤0.01% 1215
2019
Q2 		$13.1M Buy
67,353
+16,957
+34% +$3.66M ﹤0.01% 1272
2019
Q1 		$13.3M Sell
50,396
-16,759
-25% -$3.06M ﹤0.01% 1274
2018
Q4 		$13.4M Buy
67,155
+320
+0.5% +$97.5K ﹤0.01% 1255
2018
Q3 		$41.6M Buy
66,835
+33,502
+101% +$14.9M 0.01% 984
2018
Q2 		$11.4M Buy
+33,333
New +$12M ﹤0.01% 1325

Other funds holding TECX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

T. Rowe Price Associates's TECX Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Tectonic Therapeutic (TECX) stake by 71% in Q2 2026, selling an estimated $3.41M and leaving 48,001 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2101.

T. Rowe Price Associates first reported a position in TECX in Q2 2018 and has held it in 15 quarters since. The position peaked at $41.6M in Q3 2018. 122 funds tracked by Wall St. Rank hold TECX as of Q2 2026.

  • T. Rowe Price Associates held 48,001 shares of Tectonic Therapeutic worth $1.65M as of Q2 2026.
  • T. Rowe Price Associates sold 116,054 Tectonic Therapeutic shares in Q2 2026, an estimated $3.41M.
  • Tectonic Therapeutic made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2101 holding.
  • T. Rowe Price Associates first reported a position in Tectonic Therapeutic in Q2 2018 and has held it in 15 quarters since.
  • T. Rowe Price Associates's Tectonic Therapeutic position peaked at $41.6M in Q3 2018.
  • 122 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.